• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Myocardial Infarction (1969)
Event Date 01/01/2021
Event Type  Injury  
Event Description
Heart attack [myocardial infarction].Case (b)(4) is a serious spontaneous case received from a health professional via a sales representative in united states.This report concerns a male patient of unknown age, who experienced a heart attack during treatment with euflexxa (sodium hyaluronate) solution for injection unknown route and concentration 1 dose, for unknown indication from (b)(6) 2021 to an unknown stop date.The medical assistant reported that the patient had his first injection on (b)(6) 2021 and then had a heart attack (unspecified time frame between first injection and heart attack).The patient did not receive the second or third injection due to the need for extensive care.The reporter stated that the patient will be continuing with injections.The heart attack was medically significant.Action taken with euflexxa was unknown.At the time of this report, the outcome of heart attack was recovered.Concomitant medication and medical history were not reported.All events in the case were reported as serious.At the time of reporting the case outcome was unknown.Sender comment: very limited and important information has not been reported for this case including the patient's medical history, laboratory findings, concomitant medication, product indication, event onset date etc.Preventing a proper medical assessment.Based on the known safety profile, when used according to label, it is considered highly unlikely that euflexxa caused the patient's heart attack.Company causality unrelated.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: not related.Other case numbers: internal # - others = (b)(4).This ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it does not meet the definition of a medical device incident according to the requirements of the medical device directive/ because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1% SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS  83104
MDR Report Key12520625
MDR Text Key282331705
Report Number3000164186-2021-00041
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
PMA/PMN Number
P010029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial
Report Date 09/23/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 09/14/2021
Initial Date FDA Received09/23/2021
Patient Sequence Number1
Patient Outcome(s) Other;
-
-